EUVIMEDAvasta EUVIMED
BeobachtungsstudieKohortenstudieOpen access · CC BY-NC-ND 4.0

Improving prediction of fetal/neonatal intracranial hemorrhage in HPA ‐1a alloimmunized pregnancies to guide antenatal management: An observational cohort study

Siw Leiknes Ernstsen iD, Maria Therese Ahlen, Eirin Listau Bertelsen, Jens Kjeldsen-Kragh iD, Anne Husebekk, Heidi Tiller iD

Acta Obstetricia et Gynecologica Scandinavica · 2025-10 · 104 (10) · 1859-1868

DOI: 10.1111/aogs.70031 ↗

At a glance

Beobachtungsstudie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2025-08-20. Written by Siw Leiknes Ernstsen and 5 co-authors. Institution: Norwegian National Unit for Platelet Immunology, University Hospital of North Norway, Department of Laboratory Medicine, Division of Diagnostics, Uni…. Major MEDLINE topics: Intracranial Hemorrhages, Thrombocytopenia, Neonatal Alloimmune, Antigens, Human Platelet, Prenatal Care. Cited 7 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Introduction

Maternal alloimmunization against human platelet antigen‐1a (HPA‐1a) may lead to severe intracranial hemorrhage (ICH) in the fetus or newborn as a life‐threatening complication of fetal neonatal alloimmune thrombocytopenia (FNAIT). Most women who are HPA‐1a‐alloimmunized do not have a fetus/neonate with ICH. In the absence of predictive tools to identify pregnancies with high risk of ICH outcome, most countries offer weekly antenatal IVIg to all recognized HPA‐1a‐alloimmunized pregnancies. Norwegian FNAIT guidelines are restrictive regarding antenatal IVIg administration and have a long‐standing tradition of longitudinal anti‐HPA‐1a antibody measurements when at‐risk pregnancies are identified, facilitating exploration of the natural history of alloimmunized pregnancies. We aimed to explore associations between maternal anti‐HPA‐1a antibody levels and risk of fetal/neonatal ICH in non‐IVIg treated HPA‐1a alloimmunized pregnancies and assess if an antibody level threshold can be useful for identifying pregnancies with increased ICH risk. Material and Methods We compared anti‐HPA‐1a levels both from clinically referred and prospectively identified, non‐IVIg treated, HPA‐1a‐immunized pregnancies stratified by previous neonatal FNAIT outcome (ICH or FNAIT without ICH) in Norway 1997–2023.

Results

Anti‐HPA‐1a levels in pregnancies with ICH outcome were higher (median 29.6 IU/mL, range 0.1–222.1, n = 15) compared to no ICH FNAIT pregnancies (median 10.4 IU/mL, range 0.0–83.1, n = 55; p = 0.046, Mann–Whitney U test). A suggestive anti‐HPA‐1a threshold of 70 IU/mL was chosen based on receiver operating characteristic (ROC) analysis, with high specificity values (96.4%).

Conclusion

Antenatal anti‐HPA‐1a levels may be useful when assessing the risk of ICH outcome and may enable a more targeted antenatal IVIg treatment both in a nonscreening and screening situation.

Subjects

MeSH terms (MEDLINE)

Intracranial HemorrhagesThrombocytopenia, Neonatal AlloimmuneAntigens, Human PlateletPrenatal CareIntegrin beta3HumansFemalePregnancyInfant, NewbornAdultNorwayCohort StudiesProspective StudiesImmunoglobulins, Intravenous

Author keywords

alloimmunizationantenatal managementimmunoglobulinsintracranial hemorrhagenewbornthrombocytopenia

Substances

Antigens, Human PlateletITGB3 protein, humanIntegrin beta3Immunoglobulins, Intravenous

Authors and institutions

  • Norwegian National Unit for Platelet Immunology, University Hospital of North Norway, Department of Laboratory Medicine, Division of Diagnostics, University Hospital of North Norway, Tromsø, Norway.
  • Immunology Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
  • Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
  • Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway.

ORCID profiles: Siw Leiknes Ernstsen, Jens Kjeldsen-Kragh, Heidi Tiller

Cite

APA

Ernstsen, S. L., Ahlen, M. T., Bertelsen, E. L., Kjeldsen-Kragh, J., Husebekk, A., & Tiller, H. (2025). Improving prediction of fetal/neonatal intracranial hemorrhage in HPA ‐1a alloimmunized pregnancies to guide antenatal management: An observational cohort study. Acta Obstetricia et Gynecologica Scandinavica, 104(10), 1859-1868. https://doi.org/10.1111/aogs.70031

Vancouver

Ernstsen SL, Ahlen MT, Bertelsen EL, Kjeldsen-Kragh J, Husebekk A, Tiller H. Improving prediction of fetal/neonatal intracranial hemorrhage in HPA ‐1a alloimmunized pregnancies to guide antenatal management: An observational cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2025;104(10):1859-1868. doi:10.1111/aogs.70031

BibTeX
@article{Ernstsen2025,
  author = {Ernstsen, Siw Leiknes and Ahlen, Maria Therese and Bertelsen, Eirin Listau and Kjeldsen-Kragh, Jens and Husebekk, Anne and Tiller, Heidi},
  title = {Improving prediction of fetal/neonatal intracranial hemorrhage in HPA ‐1a alloimmunized pregnancies to guide antenatal management: An observational cohort study},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  volume = {104},
  number = {10},
  pages = {1859--1868},
  doi = {10.1111/aogs.70031}
}
Start for free →